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Abstract
Discovering robust prognostic gene signatures as biomarkers using genomics data can be challenging. We have
developed a simple but efficient method for discovering prognostic biomarkers in cancer gene expression data
sets using modules derived from a highly reliable gene functional interaction network. When applied to breast
cancer, we discover a novel 31-gene signature associated with patient survival. The signature replicates across 5
independent gene expression studies, and outperforms 48 published gene signatures. When applied to ovarian
cancer, the algorithm identifies a 75-gene signature associated with patient survival. A Cytoscape plugin
implementation of the signature discovery method is available at http://wiki.reactome.org/index.php/
Reactome_FI_Cytoscape_Plugin
Background
A key goal in the application of genomics to disease is
the identification of clinically relevant biomarkers that
can distinguish otherwise indistinguishable patient sub-
types. Laboratory tests based on these biomarkers can
aid clinicians in identifying patients who are at higher
risk of developing aggressive disease and thus would
benefit from earlier, more aggressive therapy [1,2]. Bio-
marker-based tests can also guide clinicians in the
choice of therapies most likely to benefit distinct patient
groups [3-5].
Over the past decade, it has become clear that single
biomarkers, such as the expression level of a particular
protein, often do not perform as well as signatures cre-
ated from ensembles of dozens or hundreds of genes,
typically the expression levels of a panel of genes [6].
For example, Van de Vijver et al. [7] have built a classi-
fication system for breast cancer based on the gene
expression profile of 70 genes, and found that their clas-
sifier outperforms standard systems based on clinical
and histologic criteria. Pawitan et al. [8] have developed
a 64-gene signature to predict the response to therapy
of patients with breast cancer.
Several researchers have explained the observation
that multi-gene signatures are more effective than single
gene expression values by postulating that it is the net-
work of gene interactions that underlies the phenotypes
displayed by cells and that it is critical to understand
normal and abnormal phenotypes through the lens of
biological network perturbations [9]. In a recent review,
Barabási, et al. [10] promoted network-based approaches
for new cancer drug development and personalized
medicine.
A variety of network-based analytic approaches of
microarray gene expression data sets have recently been
taken to search for gene signatures that are related to
clinical outcomes in several cancers [11-16]. All of these
are supervised algorithms in which the clinical para-
meter of interest, such as the disease-free survival of
treated patients, informs the search for correlated net-
work properties. The disadvantage of supervised algo-
rithms is that they are prone to overtraining: a signature
developed on one series of patients may fail to perform
well on a different one.
Breast cancer is one of the leading causes of cancer
death worldwide [17], and the most common cancer
among women [18]. Expression of the cell surface pro-
tein biomarkers estrogen receptor (ER) and progesterone
receptor (PR) have long been associated with a more
favorable prognosis, while the presence of an amplifica-
tion in the HER2/neu gene confers sensitivity to the tar-
geted chemotherapeutic agent herceptin [19,20]. In
recent years, breast cancer has become a favorite model
for the development and testing of multi-gene
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prognostic signatures due to the heterogeneity in its
clinical presentation and progression. Serous adenocarci-
noma of the ovary is the leading cause of death from
gynecological cancers in the United States, with over
22,000 new cases and 15,500 deaths per year [21]. In
contrast to breast cancer, few independently replicated
prognostic signatures exist for this disease [22].
In this paper, we describe a semi-supervised algorithm
that first discovers modules of interacting genes involved
in the disease process independently of clinical status,
and then identifies clinically significant modules using
the supervised principal component (superpc) method
[23]. We apply this algorithm to breast cancer expres-
sion data to find a novel network module signature of
31 genes that is significantly related to breast cancer
patient survival across five independent patient series.
We then apply this method to a recent high-grade ser-
ous ovarian cancer expression data set to find a novel
network module of 75 genes significantly correlated
with patient survival. Both signatures outperform other
well-known prognostic signatures as measured by statis-
tical significance across independent data sets. The suc-
cess of the technique on two very different tumor types
suggests that it may be effective for other cancers as
well.
Results
Our method for discovering prognostic signatures builds
on top of a human protein functional interaction (FI)
network constructed by combining curated and uncu-
rated data sources using a machine learning technique
[24]. This FI network covers roughly half of annotated
human proteins, and is highly reliable based on a variety
of metrics, including confirmation of its predictions by
domain experts [24]. The network as a whole is
unweighted, and is not specific for any particular tissue
or phenotype.
Identifying disease-specific gene interaction modules
The method applies to gene expression data sets in tis-
sue samples from the disease of interest (Figure 1),
typically, but not necessarily, obtained via expression
microarray. We first calculate the Pearson correlation
coefficients (PCCs) among all functional interaction
pairs in the gene expression data set. We then assign
the PCCs to the edges of the FI network, thereby con-
verting an unweighted generic graph into a weighted
disease-specific graph. Next, we use a highly efficient
network clustering algorithm, MCL (Markov cluster-
ing) [25], to cluster the weighted network into a series
of gene interaction modules. Each module consists of a
set of genes that are both topologically close in the tis-
sue-agnostic protein FI network, and highly correlated
by expression level in the disease-specific expression
data set.
The MCL step generates many network modules, the
majority of which are very small, and contain two or
three genes only. We filter the modules passed to the
next step of analysis by removing those that are smaller
than an arbitrary threshold n, and which have an aver-
age PCC below a second arbitrary threshold p. We typi-
cally select n = 8 and p = 0.25.
From the filtered list of modules, we create a module-
based gene expression matrix with the original expres-
sion data set, which provides a mean expression level
for each module across each tissue in the series. We
then apply this expression matrix for the superpc analy-
sis [23] to search for linear combinations of network
modules that are significantly correlated with patient
survival or other clinically relevant criteria.
Discovery and validation of candidate prognostic
modules in breast cancer
Our approach is divided into two phases: prognostic
module discovery and validation. For module discovery,
we used a breast cancer tissue microarray expression
data set published in 2002 [7], henceforward known as
the ‘Nejm’ set. For validation, we used a total of four
independent breast cancer microarray expression data
sets (Table 1). The Nejm set contains gene expression
data and clinical information for samples derived from
295 patients with primary invasive breast carcinomas,
and the four validation data sets contain samples
derived from between 158 and 372 patients each, for a
total of 1,233 independent patients. Notably, different
microarray platforms were used for each of the discov-
ery and validation sets, except for GSE4922 [26] and
GSE1456 [8], which are composed of non-redundant tis-
sue samples analyzed on the same platform. In each
patient series, survival was defined as the number of
years or months from initial pathological diagnosis of
the tumor until patient demise or loss to follow-up.
However, the time durations for GSE4922 are for dis-
ease free survival times since only disease free survival
times are provided in this data set.
In the discovery set, 30 modules ranging in size from
8 to 70 genes passed the filters. We numbered these
from 1 to 30 in order of decreasing module size. Based
on these modules, we generated a module-based gene
expression matrix by using mean expression level for
each module across 295 breast cancer samples, and sub-
jected this matrix to superpc analysis. Superpc ten-fold
cross-validation [23] results show an optimal threshold
value at 1.20, which yields 8 modules comprising 165
genes. We then validated the trained superpc model
based on the selected network modules against four
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Figure 1 Schematic workflow for network module searching based on gene expression data using a functional interaction network.
Table 1 Five breast cancer data sets used in this study
Data set Sample size Cancer type Microarray platform Reference
Nejm 295 Primary invasive breast carcinoma Agilent Hu25K [7]
GSE1456 159 Primary breast cancer Affymetrix Hu133A, Hu133B [8]
GSE18229 372 Invasive breast carcinoma Agilent 1A, Agilent custom array [64]
GSE3143 158 Primary breast tumor Affymetrix Hu95Av2 [65]
GSE4922 249 Primary breast cancer Affymetrix Hu133A, Hu133B [26]
The Nejm data set was used as the training data set for searching for network modules that are clinically significant, and the other four data sets were used as
test data sets.
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independent breast cancer data series. The results
(Table 2) show that the same first principal component
is significantly related to patient overall survival across
five breast cancer data sets with P-values ranging from
4.1 × 10-3 to 6.7 × 10-11.
In order to assess the robustness of our signature-
finding algorithm, we used each of four validation data
sets as the training data set, and the remaining four as
the validation data sets (Tables S1 to S4 in Additional
file 1). Except for results related to GSE3143, all trained
superpc models yielded highly similar prognostic mod-
ules as measured by gene overlap: using a hypergeo-
metric test for the statistical significance of the overlap
yielded P-values ranging from 1 × 10-11 to 1.7 × 10-78
(Table S5 in Additional file 1).
When applied to GSE3143, the training procedure
selected four MCL modules that contained a distinct set
of genes from those selected by the other data sets, and
yielded much wider 95% confidence intervals on the
hazard ratios derived from these modules (Table S2 in
Additional file 1). This may result from poor quality of
this data set, a different patient or tumor population, or
unknown factors. However, the trained superpc model
using GSE3143 as the training data set remained
significant across all five data sets (Table S2 in Addi-
tional file 1).
MCL can be used for finding network clusters based
on the original unweighted, tissue-agnostic FI network.
By assigning gene co-expression values as weights for
the FI network, we hope to find network modules con-
taining genes having similar expression patterns in a dis-
ease, and expect these modules are better features to
model disease heterogeneity. We compared the weighted
approach to an unweighted approach and found that the
weighted approach has better performance (Table S6 in
Additional file 1) based on both R2 values, which are
used to measure the performance of survival models
[23], and P-values. The unweighted approach also failed
to yield significant results for the ovarian cancer data
sets (see below).
Module 2 is significant across five breast cancer data sets
Our earlier results show that training with the Nejm
data set yields a superpc model with the best P-values
across all validation sets. We therefore investigated the
structure of this signature in more detail by assessing
the contribution of each individual network module to
the signature’s superpc model.
Using the univariate Cox proportional hazards (Cox
PH) model [27,28] to measure the correlation of mean
expression level of each of eight modules selected by the
trained superpc model to patient survival time (Table 3),
we found that each module is correlated with patient
overall survival at P-values ≤ 0.002. However, the most
striking of these was module 2, a set of 31 genes with a
hazard ratio of 1.3 and having the lowest P-value of 1.75
× 10-10. This P-value remains significant after strict Bon-
ferroni correction (27 tested MCL modules, adjusted P-
value 4.7 × 10-9). By repeating the Cox PH analysis on
each validation data set, we found that module 2 alone
is consistently correlated with survival in all four of the
sets (Table 3). Furthermore, it has the lowest P-values
in four validation data sets, ranging from 1.64 × 10-4 in
GSE18229 to 6.70 × 10-6 in GSE3143. For this reason,
we examined module 2 in more detail.
We partitioned samples in each data set into two
groups corresponding to high and low module 2 expres-
sion based on the median expression level of genes in
the module and generated Kaplan-Meier survival curves
(Figure 2). In each case, high module 2 expression is
associated with significantly shorter survival.
Because the studies used diverse array platforms, the
absolute expression score for module 2 that we chose as
the pivot point differed among the studies. The need to
calculate the pivot point from a population of patient
samples is an obstacle to using module 2 as a potential
prognostic test. However, we found that a simple
Table 2 Superpc continuous prediction results from




HR 5.21E+00 2.28E+00 1.98E+00
95% HR CI 3.18 to 8.56 1.19 to 4.34 1.02 to 3.83
P-value 6.68E-11 1.25E-02 4.26E-02
GSE4922
HR 7.35E+00 2.05E-01 2.66E-02
95% HR CI 2.11 to 25.6 0.0091 to 4.62 6.5e-4 to 1.08
P-value 1.73E-03 3.19E-01 5.51E-02
GSE3143
HR 7.27E+02 6.10E-03 1.70E+00
95% HR CI 8.1 to 6.5e+4 1.8e-4 to 0.21 1.1 to 2.6
P-value 4.12E-03 4.61E-03 1.19E-02
GSE18229
HR 5.34E+00 7.20E+00 9.31E-01
95% HR CI 2.63 to 10.9 1.73 to 30.0 0.30 to 2.90
P-value 3.63E-06 6.66E-03 9.01E-01
GSE1456
HR 1.50E+02 1.45E+02 6.03E+00
95% HR CI 17 to 1287 1.66 to 1.26e+4 0.034 to 1057
P-value 5.00E-06 2.91E-02 4.96E-01
The results were generated by using the Nejm data set as the training data
set and four independent data sets as validation data with a threshold value
of 1.20 and 8 selected MCL modules. P-values less than 0.05 are in bold. CI,
confidence interval; HR, hazard ratio.
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procedure for rescaling each of the array platforms to
match the profile of the Nejm set (Figure S2 in Addi-
tional file 1) allowed us to directly compare module
expression levels across arrays and to merge all samples
from the discovery data series and all four validation
series into a single series of 1,233 patient samples. As
shown in Figure 3, the merged data set shows strikingly
different survival curves among the high and low mod-
ule 2 expression groups, and acts as a proof of principle
for using module 2 expression as a cross-platform prog-
nostic signature.
It has been reported that microarray-based gene signa-
tures are effective in ER+, but not in ER- breast cancers
[1]. We looked at the special case of triple negative (TN)
samples, which are negative for ER and PR as well as
HER2/neu amplifications, and have a poor prognosis
overall. For this analysis, we only used the GSE18229
data set since it is unique in providing information about
ER, PR and HER2 status. Figure S3 in Additional file 1
shows Kaplan-Meier survival curves for the four sample
groups: ER+/Module2+, ER+/Module2-, TN/Module2+,
and TN/Module2-. Among ER+ patients, there is a strik-
ing difference in survival between Module2+ and Mod-
ule2- patients. Among TN patients, there is no difference
in survival for the first 30 months, but after this time
there is a paradoxical increase in survival in patients with
Module2+ tumors. However, this difference is near the
borderline of significance, at P-value = 0.088, and the
Table 3 Uni-variate Cox proportional hazards analysis results for right Markov clustering modules
Nejm GSE4922 GSE3143 GSE18229 GSE1456
Module Size Hazard ratio P-value Hazard ratio P-value Hazard ratio P-value Hazard ratio P-value Hazard ratio P-value
2 31 1.30E+00 1.75E-10 1.84E+00 5.84E-05 1.55E+01 6.70E-06 1.12E+00 1.64E-04 2.46E+00 8.76E-05
18 9 9.44E-01 3.99E-09 1.35E+00 1.86E-04 2.61E+00 1.42E-01 7.23E-01 2.59E-03 2.19E+00 1.10E-04
4 17 1.14E+00 1.35E-08 2.46E+00 2.95E-04 2.18E-01 9.23E-01 1.08E+00 3.81E-03 3.38E+00 8.42E-04
13 11 1.02E+00 7.49E-07 1.84E+00 2.02E-04 6.20E-01 3.28E-01 8.66E-01 3.31E-04 2.51E+00 2.37E-04
21 8 1.75E+00 5.21E-05 2.08E+00 6.61E-02 -2.14E+00 2.48E-01 1.31E+00 3.44E-02 3.06E+00 2.93E-02
12 11 -6.59E-01 3.59E-04 -7.18E-01 3.40E-01 3.07E+00 8.43E-02 -8.81E-01 1.26E-02 -3.32E+00 1.55E-02
29 8 7.90E-01 9.21E-04 1.80E+00 5.03E-02 -1.08E-01 4.89E-01 1.25E+00 2.41E-03 3.84E+00 2.58E-03
1 70 -6.68E-01 2.05E-03 2.96E+00 2.95E-02 -1.41E-01 2.62E-01 -1.75E-01 6.38E-01 -2.04E+00 2.76E-01
The eight MCL modules were selected by the trained superpc model when the Nejm data set was used as the training data set. Modules are sorted based on P-
values. The sole module that is significant across five breast cancer data sets is in bold.
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Figure 2 Kaplan-Meier survival plots for the five breast cancer data sets. Samples in each data set were split into two groups using the
median values as the cutoff values. Green, samples having higher module 2 expression; red, samples having lower module 2 expression. Note
that the time durations for GSE4922 are for disease free survival times. (a) Results before rescaling module 2 expression values across five breast
cancer data sets. (b) Results after rescaling.
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number of patients is small (n = 59). Therefore these
results should be interpreted with caution.
As a check of the statistical significance of module 2,
we performed a permutation test on the Nejm data set
by repeatedly swapping gene expression values. In 1,000
permutations, we never found a network module with a
P-value below 1.64 × 10-4, the highest P-value, across all
five breast cancer data sets. We also performed a per-
mutation test using gene sets randomly selected from
the FI network and containing the same number of
genes as module 2, and failed to find a random gene set
with P-value below 1.64 × 10-4 across five data sets after
1,000 trials. These results indicate that module 2 was
highly unlikely to have been found by chance.
Biological role of module 2
To understand why the 31 genes comprising module 2
might be related to patient survival, we performed a
functional enrichment analysis on this module and its
subnetworks using pathways that were used to build the
FI network (Figure 4). There are two interdigitating sub-
networks in module 2, one enriched in genes annotated
as ‘Cell Cycle M Phase’ in Reactome [29], and the other
as ‘Aurora B Signaling Pathway’ in the NCI-PID
P-value = 0 





















Survival Time (month) 
Figure 3 Kaplan-Meier survival plot for the merged breast cancer data set. All samples were divided into two groups based on the
median value of module 2 expression. The green curve is for samples having higher module 2 expression, while the red curve for samples
having lower expression.
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database [30]. An enrichment analysis on Gene Ontol-
ogy cellular component annotations indicates a strong
enrichment in gene products involved in condensed
chromosome kinetochore or centromeric regions (Table
S8 in Additional file 1).
We also tested if it is possible to find a smaller subset
of genes from this module. After sorting module 2
genes based on P-values generated from the univariate
Cox PH model (Table S9 in Additional file 1), we chose
the top genes using different P-value cutoffs. Using this
approach, we found that smaller subsets of genes are
also significant across five breast cancer data sets. For
example, with a P-value cutoff 1.0 × 10-7, we identify
seven genes (highlighted in yellow in Figure 4): ARUKB,
BIRC5, BUB1, CENPN, KIF20A, NCAPD2, and SPC25.
The P-values generated from Cox analysis range from
2.0 × 10-4 to 1.2 × 10-11 for the five studies. Pathway
enrichment analysis on this smaller set of genes was
similar to the results described for the entire module 2.
Comparison between module 2 and other breast cancer
prognostic gene signatures
Many breast cancer prognostic gene signatures have
been published since the first 70-gene signature was
developed about 10 years ago [1]. We compared the
correlation significance of average gene expression and
Figure 4 Functional interaction sub-network constructed by using module 2 genes. Gene products involved in the Aurora B signaling
pathway have been encapsulated in the light brown shaded area, while gene products involved as components of the kinetochore in mitosis in
the light grey shaded area. Edges between genes indicate functional interactions (FIs). FIs extracted from pathways are shown as solid lines (for
example, AURKB®NCAPD2), while predicted ones are shown as dashed lines (for example, AURKB—ANKZF1). Extracted FIs involved in activation,
expression regulation, or catalysis are labeled with arrows. Seven genes highlighted in yellow form a smaller network module that is also
significantly related to breast cancer patient survival across five patient data sets.
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breast cancer patient overall survival between our mod-
ule 2 and 48 gene signatures collected and reported by
Venet et al. [31] across five breast cancer data sets. In
order to compare the gene signature performance across
all five breast cancer data sets, we used the negative
logarithm of geometric mean of P-values from five
breast cancer data sets based on the univariate Cox PH
model as the score (P-value score). The higher this
score, the better a gene signature performs. Figure 5 is
the plot of P-value scores for module 2 and 48 pub-
lished gene signatures, and shows that module 2 has the
best performance across five breast cancer data sets. For
any individual data set, however, the module 2 signature
never has the top ranked P-value (Figure S5 in Addi-
tional file 1). We take these results as evidence that the
semi-supervised nature of the signature discovery algo-
rithm leads to a gene expression signature that is more
robust than those discovered by supervised methods.
Venet et al. [31] found that many published breast
cancer gene signatures have strong expression
correlation to a cell proliferation-related gene set called
meta-PCNA, containing 131 genes that are significantly
related to PCNA gene expression. We checked the gene
expression correlation between module 2 and meta-
PCNA, and found that similar to other many published
gene signatures, module 2 expression is strongly corre-
lated to meta-PCNA across five breast cancer data sets
(Table S13 in Additional file 1). Because of this strong
correlation, multi-covariate Cox PH analysis shows that
module 2 is not independently related to patient overall
survival after adjustment for meta-PCNA gene expres-
sion in all but the GSE3143 data sets (Table S14 in
Additional file 1). Gene overlap analysis shows that 7
out of 31 genes in module 2 are shared with meta-
PCNA (P-value = 3.5 × 10-10). All the shared genes
(BIRC5, AURKB, KIF20A, NCPAD2, BUB1, CDCA8, and
MAD2L1) are among the top ten of module 2 genes
sorted by P-values based on the NEJM data set (Table
S9 in Additional file 1). These results again point to a

























































































































































































































Figure 5 Plot of P-value scores for module 2 and 48 published breast cancer gene signatures. Published gene signatures were collected
and reported by Venet et al. [31]. The P-value score is defined as the negative logarithm of the geometric average of P-values from univariate
Cox PH survival analyses from five breast cancer data sets. Signatures having P-values less than 0.05 across all five breast cancer data sets are
plotted in green.
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Application of the method to high-grade serous
adenocarcinoma of the ovary
To test our method in another cancer type, we applied
it to high-grade serous adenocarcinoma of the ovary.
We used The Cancer Genome Atlas (TCGA) ovarian
gene expression data set [32] as the training data set,
and three independent data sets (GSE9891 [33],
GSE13876 [34], GSE26712 [35]) for validation.
The primary MCL network clustering algorithm iden-
tified 27 modules of size 8 or greater in the TCGA
training set, 7 of which were selected by superpc using a
threshold value of 0.8. Using superpc’s continuous pre-
diction model, we found that the second principal com-
ponent is significantly related to ovarian cancer patient
overall survival across four independent ovarian cancer
data sets (Table S15 in Additional file 1). Superpc also
offers a ‘discrete prediction’ model in which patient
samples are divided between two groups based on the
training data set. A univariate Cox PH analysis (Table 4)
and Kaplan-Meier plot (Figure S6 in Additional file 1)
demonstrate that the second principal component dis-
tinguishes a subgroup of patients who have significantly
longer survival (hazard ratio (HR) ranging from 1.33 to
2.43 among the four data sets, P-values ranging from
3.61 × 10-2 to 8.85 × 10-5). Both results show that the
second principal component can be used as a feature to
predict samples into two groups: one contains samples
having longer survivals, while another shorter survivals.
In contrast to our results in breast cancer, we failed to
find an individual module that was significantly related
to patient overall survival across the training set and all
three validation sets. So we used the six network
modules selected by superpc and built a functional
interaction subnetwork of 75 genes (Figure S7 in Addi-
tional file 1). Pathway annotations show that the major-
ity of these modules are related to interleukin 2 and T-
cell receptor signaling transduction pathways, cell adhe-
sion, cell cycle, and homologous recombination.
Recently, Mankoo et al. [22] used the same TCGA
data set to identify prognostic signatures for progres-
sion-free survival (PFS; 181 genes) and overall survival
(219 genes) in ovarian cancer using information from
copy-number alteration, mRNA expression, microRNA
expression, and RNA methylation data. We compared
their mRNA overall survival signature to the 75-gene
signature derived from MCL+superpc. In comparison to
the Mankoo signature, the MCL+superpc signature is
almost one-third of its size, and performs better across
the same three ovarian cancer data sets used. The Man-
koo et al.’s mRNA signature yields P-values ranging
from 0.18 to 0.014 (Kaplan-Meier plot using t-score;
Figure 1 SC in File S1 in [22]), or from 0.71 to 0.048
(Kaplan-Meier plot using c-score). In contrast, the
MCL+superpc signature shows P-values from 0.036 to
0.017, which are significant across all data sets.
Cytoscape plug-in
We have packaged the workflow of module discovery,
and survival analysis, except the superpc analysis, into a
software tool that runs within a popular biological net-
work analysis platform, Cytoscape [36]. This tool is
called the Reactome FI plug-in and can be downloaded
from [37]. We also provide a detailed user guide and
example data sets. The plugin operates by making
RESTful requests against Java and R server-side services
that reside at the Reactome server. The code underlying
the plugin and server-side services is available under an
open source license that allows for unrestricted use,
modification and redistribution.
Discussion
In this paper we describe a simple and rapid procedure
to combine disease-specific gene expression data with a
static protein functional interaction network in order to
identify candidate prognostic network modules. We
apply this method to breast cancer, and find a network
module enriched in Aurora B signaling and kinetochore
components, whose expression is strongly anticorrelated
with breast cancer patient survival. The network module
was validated in four independent data sets, across a
total of more than 1,200 patients.
It is widely believed that modular structures exist in
protein interaction networks and other biological net-
works [10]. In his recent review, Barabási [10] proposed
that three types of network modules can be extracted
from protein interaction networks: topological modules,
Table 4 Superpc discrete prediction results
Data set Prediction results
TCGA
HR 1.33E+00












95% HR CI 1.08 - 2.25
P-value 1.75E-02
The TCGA data set was used as the training data set, and the second principal
component was used as the feature for prediction. The first column shows the
data sets. CI, confidence interval; HR, hazard ratio.
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functional modules and disease modules. Topological
modules are sets of interacting proteins that tend to link
to each other instead of to others; functional modules
are graph components that confer specific cellular func-
tions; and disease modules are graph components
underlying one or more diseases. Our approach links
these three kinds of modules together by using MCL
network clustering to detect topological modules in a
functional interaction network weighted by disease-spe-
cific expression data. By weighting the edges in the FI
network using gene co-expressions, we find network
modules comprising genes having similar expression
profiles in a disease. At least in the breast cancer model,
weighted MCL modules yield more robust signatures
than unweighted modules, implying that the weighted
modules catch network patterns related to heterogeneity
in a disease.
The candidate breast cancer prognostic module that
we have found contains 31 genes and combines compo-
nents of Aurora B kinase signaling, the cell cycle M
phase, and kinetochore maintenance. Uncontrolled cell
proliferation is the major phenotype displayed by cancer
cells [38] and multiple studies have connected increased
metrics of mitotic activity to poorer patient survival in
breast cancer [39-41]. This is consistent with our obser-
vation that increased expression among the genes com-
prising the module is associated with poorer overall
patient survival. The strong correlation between meta-
PCNA [31] and module 2 also implies that proteins in
module 2 are related to cell proliferation. The majority
of currently published gene signatures are related to cell
proliferation too [1,31]; nevertheless our module 2-
based signature is more robust, and performs better
than those signatures across five breast cancer data sets,
including more than 1,200 patients in total.
The aurora kinases are a family of serine-threonine
kinases that are key regulators of mitosis and many sig-
naling pathways, and evidence is accumulating that
these proteins play an important role in the malignant
cell cycle [42]. There are three members of this family
in human: Aurora kinase A (AURKA), B (AURKB), and
C (AURKC). Currently, most research efforts have been
focused on AURKA protein, and evidence indicates that
AURKA expression, but not AURKB expression, is pre-
dictive of patient survival in breast cancer [43]. The
module we have found contains both AURKB and
AURKC, but not AURKA. Survival analysis using the
univariate Cox PH model with single gene expression
shows that AURKB, but not AURKC, expression is sig-
nificantly related to patient survival in five breast cancer
data sets (Table S9 in Additional file 1). Furthermore,
one of AURKB’s functions in human cells is to ensure
proper kinetochore-microtubule attachments [42],
raising the possibility that the signature we have identi-
fied may act by virtue of its effect on kinetochore main-
tenance in addition to, or instead of, its effect on
mitotic rate.
We observe that breast cancer module 2 expression is
strongly correlated with ER status (Table S12 in Addi-
tional file 1). The Reactome functional interaction net-
work in fact does predict an interaction between ESR1
and ITBG3BP, a member of module 2. Talukder et al.
[44] showed that ITBG3BP is an estrogen inducible
gene; ITBG3BP protein also associates with endogenous
ER and acts as a transcriptional co-regulator of ER tar-
get genes [44]. ITBG3BP has also been found to be
involved in assembly of a proximal CENP-A nucleosome
associated complex (NAC), which is essential to the
function of the kinetochore to maintain correct chromo-
some alignment and segregation during mitosis [45].
This suggests a direct connection between ER status
and module 2 expression, but contradictory to our find-
ing of anti-correlation between module 2 expression and
ER level. Besides this direction connection between
ESR1 and module 2, there are many indirect connec-
tions via FIs in the FI network. We will analyze these
indirect connections to see why there is anti-correlation
between module 2 expression and ER level.
Network-based approaches are different from gene
based approaches [7,8,46]. In network based approaches,
protein interaction networks are used in gene signature
search. Genes in found signatures usually interact with
each other, are involved in the same pathways, and have
similar biological functions. Chuang et al. [14] showed
that network-based approaches perform better in cancer
metastasis prediction than gene-based approaches. Simi-
lar to what Chuang et al. [14] showed before, our net-
work module-based approach shows more consistent
performance across different data sets than the gene-
based approach in the superpc analysis.
Several methods have been published for using protein
interaction networks to search for clinically relevant net-
work components, subnetworks or modules [14-16,47].
The most popular one is the greedy search algorithm
[47]. Our weighted MCL network module search
method runs much faster than the greedy based network
module search approach: 20 second versus 6 hours (see
the supplementary results in Additional file 1 for
details). During greedy search, the majority of running
time has to be spent calculating Cox PH scores for each
potential network module in order to find final modules.
However, there is no need to run CoxPH survival analy-
sis in MCL network clustering.
Currently, all published network module search meth-
ods work in a supervised manner in which the pheno-
type information is used during the component search
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process as all gene-based approaches [7,8,46] do. We
use an unsupervised approach for module construction
in which the only inputs are gene coexpression values
and the static functional interaction network. We believe
this use of an unsupervised approach contributed to the
success of validating the candidate prognostic module
against multiple independent data sets. Indeed, the
supervised greedy search algorithm shows a serious
over-training problem, with much bigger performance
differences based on P-values between the training data
set and the testing data sets (Tables S1 and S7 in Addi-
tional file 1). We observed similar over-training issues
when we applied linear regression methods to MCL net-
work modules (data not shown).
Horvath and colleagues [48,49] have developed a fra-
mework for network-based analysis using a weighted
correlation network based on expression data sets. Our
approach differs from theirs in that they construct the
network based on gene expression correlation directly,
while we use a pre-built static functional interaction
network. In the Horvath methodology, the edges
between two genes in the weighted co-expression net-
work may not necessarily mean direct functional rela-
tionships, while those built from functional interactions
were built from a combination of human curated path-
ways and predicted interactions supported by multiple
independent data sources. We believe this increases the
likelihood that the candidate module-based signatures
we find reflect true functional units in the cell.
The application of our MCL+superpc approach to
high grade serous adenocarcinoma of the ovary identi-
fied 6 modules comprising 75 genes that appear to be
associated with patient overall survival in ovarian cancer.
These modules are related to immune system function,
cell adhesion, and cell cycle activity. Several groups have
published ovarian cancer signatures based on microarray
expression profiles. Most, if not all, of these signatures
were developed using individual genes without consider-
ing network context during signature search. Many of
the studies had small sample sizes [35,50,51], or were
not validated using independent data sets [51]. Very
recently, however, Mankoo et al. [22] used the same
data sets that we use here to study signatures for both
progression-free survival and overall survival in ovarian
cancer. These authors integrated features from copy-
number alteration, mRNA expression, microRNA
expression, and RNA methylation data. Even so, the sig-
nature discovered by our MCL module-based method
combined with superpc outperformed theirs across the
three shared ovarian cancer data sets, suggesting that
simple gene expression values, when combined with a
priori network information, can yield prognostic signa-
tures comparable to those derived by combining diverse
molecular features.
Conclusions
We report a new network-based approach to identify
functional interaction modules in gene expression data
sets, used it to find a novel 31-gene signature that is
strongly correlative with poor patient survival in ER-
positive breast ductal adenocarcinoma patients, and vali-
dated the signature in five independent patient series.
This network module is related to Aurora kinase B sig-
naling and kinetochore assembly during mitosis. Using
this approach, we have also identified a 75-gene signa-
ture that is correlated with survival in high-grade serous
adenocarcinoma of the ovary. We have packaged the
algorithms in a software package that is available for
unrestricted use and redistribution.
Materials and methods
Functional interaction network construction
The functional interaction network used in this study
was described in Wu et al. [24]. Briefly, we compiled
protein pairwise relationships extracted from protein-
protein interactions from human, yeast, worm, and fly,
gene co-expression data sets, Gene Ontology annota-
tions, domain-domain interactions, and text-mined pro-
tein interactions. We then trained a naïve Bayes
classifier based on these pairwise relationships by using
a training data set extracted from curated pathways
from Reactome [29]. The trained naïve Bayes classifier
was used to predict functional interactions for protein
pairs, and the predicted FIs merged with FIs extracted
from curated pathways in Reactome, KEGG [52], NCI-
PID [30], Panther [53] and CellMap [54]. The final FI
network contains 10,956 proteins, and 209,988
interactions.
MCL network clustering
We chose MCL [25] as the network-clustering algorithm
in order to take advantage of edge weights. We weighted
each interaction edge according to the absolute value of
the PCC of the expression levels of the two genes con-
nected by the edge. To control the size of network mod-
ules generated from the MCL clustering, we used 5.0 as
the inflation coefficient. For breast cancer data analysis,
we chose MCL modules of size 8 or greater, and average
PCC no smaller than 0.25. In the breast cancer data set,
these two filters yielded 30 MCL modules comprising
401 genes. For permutation testing, we randomly
swapped expression values for all genes, or randomly
selected genes from the FI network.
Greedy network module search
Following the method described in Chuang et al. [14],
we implemented a greedy network component search
method in Java to search for network modules signifi-
cantly related to patient overall survival. We used a Java
Wu and Stein Genome Biology 2012, 13:R112
http://genomebiology.com/2012/13/12/R112
Page 11 of 14
package called JavaStatSoft [55] to do Cox PH survival
analysis, and used the negative logarithm of P-values
from the Cox PH model as component scores during
network searching. The search depth was 1 and max
depth was 2.
Superpc analysis
For the superpc analysis, we used the R package superpc
downloaded from CRAN [56], and followed the instruc-
tions on the authors’ web site [57]. To use the second
principal component as the feature for discrete predic-
tion in the ovarian cancer data analysis, we modified the
original R source code. For gene-based superpc analysis
for the breast cancer data sets, we grouped a set of
1,849 genes that are shared across all five breast cancer
data sets. For the ovarian cancer data analysis, we did a
z-score transformation on MCL module-based gene
expression matrices.
Breast cancer data sets
The five breast cancer data sets were downloaded from
published sources. The Nejm [7] data set was down-
loaded from the authors’ web site [58]. It contains a
gene expression data set and clinical information for
295 primary breast cancer patients. The other four
breast cancer data sets, which were used as validation
data, were downloaded from GEO [59]. See Table 1 for
detailed information. We downloaded SOFT formatted
family files, extracted clinical information, and mapped
probes to genes based on annotations in the down-
loaded files using an in-house Java parser. Probes that
could be mapped to multiple genes were removed. In
cases in which multiple probes were mapped to the
same gene, we used averaged values for multiple probes
as the gene expression value. All gene expression data
sets have been z-score transformed as described in [60]
before further analyses. To classify breast cancer sam-
ples in the data sets, we used the downloaded R code
for the PAM50 classifier from [61].
Ovarian cancer data sets
Four ovarian cancer data sets have been used. The
TCGA ovarian cancer data set [32] was provided by the
TCGA analysis group. The other three data sets,
GSE9891 [33], GSE13876 [34], and GSE26712 [35], were
downloaded from GEO, and were pre-processed as for
the breast cancer data sets.
Survival analysis
We used R [62] for both the Cox PH model [27] and
Kaplan-Meier survival analysis [28]. P-values reported in
Results were based on the Wald test for the Cox PH
model, and log-rank test for Kaplan-Meier analysis. To
assign an expression score to a module generated from
the MCL clustering, we took the mean gene expression
value for all genes contained in the module.
Reactome FI Cytoscape plug-in development
We have implemented the signature discovery proce-
dures described here as a Cytoscape plug-in [36], which
uses a lightweight client and server two-tier architecture.
The major analysis functions were implemented in the
server side and exposed in RESTful APIs. The client-
side Cytoscape plug-in is used to display the results
returned from the server-side. This plug-in has been
configured so that it can be launched via Java Web Start
[63], or can be installed by downloading a jar file and
placed into the plug-in folder in the Cytoscape applica-
tion. The source code can be downloaded by following a
link from the user guide page [37].
Additional material
Additional file 1: Supplementary results.
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